JPS6016997A - オピオイド分解酵素阻害剤 - Google Patents
オピオイド分解酵素阻害剤Info
- Publication number
- JPS6016997A JPS6016997A JP12572583A JP12572583A JPS6016997A JP S6016997 A JPS6016997 A JP S6016997A JP 12572583 A JP12572583 A JP 12572583A JP 12572583 A JP12572583 A JP 12572583A JP S6016997 A JPS6016997 A JP S6016997A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- compound shown
- group
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000790 Enzymes Proteins 0.000 title abstract description 17
- 102000004190 Enzymes Human genes 0.000 title abstract description 17
- -1 Organogermanium compound Chemical class 0.000 title abstract description 11
- 230000002401 inhibitory effect Effects 0.000 title abstract description 5
- 239000003112 inhibitor Substances 0.000 title abstract description 3
- 239000003795 chemical substances by application Substances 0.000 title description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 230000000593 degrading effect Effects 0.000 claims description 10
- 150000002291 germanium compounds Chemical class 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000002075 main ingredient Substances 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 35
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 10
- 229960005181 morphine Drugs 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 239000003960 organic solvent Substances 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 abstract description 3
- 206010012335 Dependence Diseases 0.000 abstract description 3
- 150000001408 amides Chemical class 0.000 abstract description 3
- 230000003533 narcotic effect Effects 0.000 abstract description 3
- 230000001077 hypotensive effect Effects 0.000 abstract description 2
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 239000012320 chlorinating reagent Substances 0.000 abstract 1
- 230000026781 habituation Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 229910052796 boron Inorganic materials 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229940005483 opioid analgesics Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910052732 germanium Inorganic materials 0.000 description 6
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 6
- 108010092674 Enkephalins Proteins 0.000 description 5
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- XRYJTKGEJGVBCC-UHFFFAOYSA-N 2-germylpropanoic acid Chemical compound CC([GeH3])C(O)=O XRYJTKGEJGVBCC-UHFFFAOYSA-N 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- XEABSBMNTNXEJM-UHFFFAOYSA-N propagermanium Chemical compound OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O XEABSBMNTNXEJM-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IQULGZQMMPRBLA-UHFFFAOYSA-N 2-carboxyethylgermanium Chemical compound OC(=O)CC[Ge] IQULGZQMMPRBLA-UHFFFAOYSA-N 0.000 description 1
- MIAXGDNPGHKUKI-UHFFFAOYSA-N 2-methyl-3-trichlorogermylbutanoic acid Chemical compound OC(=O)C(C)C(C)[Ge](Cl)(Cl)Cl MIAXGDNPGHKUKI-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- GIEAINOVPLDQPT-UHFFFAOYSA-N ethylgermanium Chemical compound CC[Ge] GIEAINOVPLDQPT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000008531 maintenance mechanism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000082 organogermanium group Chemical group 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002315 pressor effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- MUDDKLJPADVVKF-UHFFFAOYSA-N trichlorogermane Chemical compound Cl[GeH](Cl)Cl MUDDKLJPADVVKF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12572583A JPS6016997A (ja) | 1983-07-11 | 1983-07-11 | オピオイド分解酵素阻害剤 |
| GB08416614A GB2142635B (en) | 1983-07-01 | 1984-06-29 | Organogermanium compound and an opioid peptide-degrading enzyme inhibitor containing the same |
| CH315384A CH660192B (enrdf_load_stackoverflow) | 1983-07-01 | 1984-06-29 | |
| DE3424107A DE3424107A1 (de) | 1983-07-01 | 1984-06-29 | Organogermaniumverbindung und diese als wirkstoff enthaltender opioidpeptidaseinhibitor |
| FR8410392A FR2548187B1 (fr) | 1983-07-01 | 1984-06-29 | Composes d'organo-germanium et leurs utilisations therapeutiques en tant qu'inhibiteurs des enzymes qui degradent les peptides opioides |
| US06/626,787 US4681960A (en) | 1983-07-01 | 1984-07-02 | Organogermanium compound |
| US06/930,561 US4748187A (en) | 1983-07-01 | 1986-11-14 | Opioid peptide-degrading enzyme inhibitor with a germanium compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12572583A JPS6016997A (ja) | 1983-07-11 | 1983-07-11 | オピオイド分解酵素阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61296117A Division JPS62142189A (ja) | 1986-12-12 | 1986-12-12 | 有機ゲルマニウム化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6016997A true JPS6016997A (ja) | 1985-01-28 |
| JPH0144169B2 JPH0144169B2 (enrdf_load_stackoverflow) | 1989-09-26 |
Family
ID=14917224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12572583A Granted JPS6016997A (ja) | 1983-07-01 | 1983-07-11 | オピオイド分解酵素阻害剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6016997A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61254631A (ja) * | 1985-05-04 | 1986-11-12 | Nippon Zeon Co Ltd | 感光性フレキソ版とゴムバツキング材との接着方法 |
| JPS6293293A (ja) * | 1985-10-18 | 1987-04-28 | Asai Gerumaniumu Kenkyusho:Kk | 有機ゲルマニウム化合物及びそれを主剤とした鎮痛剤 |
| JP2009114028A (ja) * | 2007-11-07 | 2009-05-28 | Olympus Corp | ガラスセルの製造方法、ガラスセル成形装置 |
-
1983
- 1983-07-11 JP JP12572583A patent/JPS6016997A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61254631A (ja) * | 1985-05-04 | 1986-11-12 | Nippon Zeon Co Ltd | 感光性フレキソ版とゴムバツキング材との接着方法 |
| JPS6293293A (ja) * | 1985-10-18 | 1987-04-28 | Asai Gerumaniumu Kenkyusho:Kk | 有機ゲルマニウム化合物及びそれを主剤とした鎮痛剤 |
| JP2009114028A (ja) * | 2007-11-07 | 2009-05-28 | Olympus Corp | ガラスセルの製造方法、ガラスセル成形装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0144169B2 (enrdf_load_stackoverflow) | 1989-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0825977B2 (ja) | Ｎ−（２▲’▼−アミノフエニル）−ベンズアミド誘導体，その製法及びそれを含有する薬剤組成物 | |
| JP3457687B2 (ja) | 白内障治療用薬剤 | |
| JPH03112933A (ja) | 抗腫瘍剤 | |
| JPH01250345A (ja) | 非ペプチド性レニン阻害剤 | |
| US4748187A (en) | Opioid peptide-degrading enzyme inhibitor with a germanium compound | |
| CA1167864A (en) | Esters of mercapto acyl-carnitines, process for their preparation and pharmaceutical compositions containing same | |
| JPH0232095A (ja) | 免疫機構の機能を仰制する新規ペプチド、それらを含む医薬組成物、並びに前記ペプチド及び医薬組成物の調製方法 | |
| NO301074B1 (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive analoger av peptidasesubstrater | |
| JPS6016997A (ja) | オピオイド分解酵素阻害剤 | |
| JPS61233665A (ja) | トリペプチド及び医薬組成物 | |
| JPS6158449B2 (enrdf_load_stackoverflow) | ||
| KR100355096B1 (ko) | 신규푸린유도체및그약학적으로허용되는염 | |
| JPH0832704B2 (ja) | プロリルエンドペプチダーゼ阻害剤 | |
| JPH0651677B2 (ja) | ジペプチド誘導体及びその製法並びに用途 | |
| JPH0228143A (ja) | アミド化合物，その製造法ならびにグルタミン酸レセプター阻害剤 | |
| EP0271443A1 (de) | N,N'-Disubstituierte Harnstoffe und Verfahren zu ihrer Herstellung | |
| JPH0348200B2 (enrdf_load_stackoverflow) | ||
| JPH05331063A (ja) | エンドセリン受容体拮抗剤 | |
| JP2589245B2 (ja) | Ｎ−（３−アルキル（またはアルケニル）−４−ヒドロキシベンゾイル）グリシン亜鉛錯体 | |
| BE839405A (fr) | Nouveaux polypeptides, leur preparation et leur application comme medicaments | |
| CA1338831C (en) | 4-thiazolidine-carboxylic acid derivatives | |
| JPS59148745A (ja) | 新規アシルグルタミルリジン誘導体 | |
| JPH1129465A (ja) | 抗潰瘍剤 | |
| JPS59231057A (ja) | カルボン酸アミド化合物およびその誘導体 | |
| FR2896801A1 (fr) | Nouveaux composes dipeptidiques, les compositions pharmaceutiques en renfermant ainsi que leur procede d'obtention |